NCI investigator John Haanen told the ESMO congress that TIL therapy improved PFS compared to Yervoy by 50%, 7.2 months versus 3.1 months with Yervoy, which was a significant improvement.

Findings showed the risk of disease progression or death was reduced by 79% with nivolumab and ipilimumab combination therapy vs chemotherapy (hazard ratio [HR], 0.21 [95% CI, 0.14-0.32]; P ...

The recent FDA approval of ipilimumab and vemurafenib for the treatment of advanced melanoma marks the first FDA-approved therapies for melanoma since 1998 and are the first drugs to show ...

pivotal Phase 3 clinical trial which evaluated the safety and efficacy of ipilimumab combined with sintilimab as neoadjuvant therapy and as compared with direct radical surgery for MSI-H/dMMR ...